Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Brown

Procedural Dermatology Orange Park, FL Medical Doctor

NPI 1447242748 CMS profile 110894

1495 Kingsley Ave, Orange Park, FL 32073

Open in the dashboard

General payments

$21,557

885 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Brown of Orange Park, FL is reported in the CMS Open Payments database as having received $21,557 across 885 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Procedural Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,367 173
2024 General $4,362 188
2023 General $3,479 128
2022 General $3,556 131
2021 General $2,387 112
2020 General $1,420 72
2019 General $1,985 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Brown
  • Procedural Dermatology median
  • Middle half of Procedural Dermatology
  • National median

In program year 2025, general payments to Robert Brown were reported at $4,367. Among 381 Procedural Dermatology profiles paid that year, the median was $592 and the middle half received between $144 and $1,778.

Show as a table
Year Robert Brown Procedural Dermatology median Middle half National median
2019 $1,985 $454 $152–$1,260 $163
2020 $1,420 $243 $90–$835 $114
2021 $2,387 $337 $102–$1,128 $132
2022 $3,556 $443 $119–$1,654 $149
2023 $3,479 $583 $137–$1,838 $160
2024 $4,362 $611 $132–$1,835 $164
2025 $4,367 $592 $144–$1,778 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $5,009 164 payments
  2. Janssen Biotech, Inc. $2,479 146 payments
  3. Genzyme Corporation $1,973 63 payments
  4. LEO Pharma Inc. $1,424 65 payments
  5. Regeneron Healthcare Solutions, Inc. $1,249 32 payments
  6. Novartis Pharmaceuticals Corporation $1,239 90 payments
  7. Lilly USA, LLC $1,153 39 payments
  8. UCB, Inc. $975 30 payments
  9. Amgen Inc. $788 41 payments
  10. Sun Pharmaceutical Industries Inc. $783 30 payments
  11. Other $4,487 185 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $21,327 881 payments
  2. Education $178 3 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $52 1 payment
Products named General payments · program years 2019–2025
  1. TREMFYA $2,496 130 payments
  2. DUPIXENT Immunology $2,245 74 payments
  3. RINVOQ $2,227 54 payments
  4. SKYRIZI $2,022 75 payments
  5. ADBRY $1,055 56 payments
  6. Bimzelx $935 28 payments
  7. HUMIRA $873 39 payments
  8. Otezla $685 33 payments
  9. DUPIXENT Inflammation And Immunology $673 20 payments
  10. SOTYKTU $643 29 payments
  11. Other $9,160 462 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

1,967

Median for Dermatology: 534

Drug cost

$701,808

Median for Dermatology: $67,151

Branded share of claims

9.9%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready (2 Pens) Secukinumab Brand 32 $236,081
Tremfya Guselkumab Brand 13 $181,287
Humira(Cf) Adalimumab Brand 13 $176,388
Dupixent Pen Dupilumab Brand 18 $67,522
Clobetasol Propionate Generic 263 $10,543
Fluorouracil Generic 60 $4,295
Metronidazole Generic 80 $3,699
Ketoconazole Generic 138 $2,362
Triamcinolone Acetonide Generic 187 $2,144
Clindamycin Phosphate Generic 71 $2,133

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$339,046

Of which drugs: $13,195

Medicare patients

1,523

Average age 76

Services billed

8,196

619 women, 904 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 31%
Ischemic heart disease 31%
Chronic kidney disease 24%
Atrial fibrillation 20%
COPD 17%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 23 207 $160

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$639 18 —
TREMFYA
$576 13 —
RINVOQ
$435 — —
ADBRY
$341 — —
SOTYKTU
$321 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

885 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Procedural Dermatology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record